As the pharma patent cliff approaches, delve into which important drugs are about to lose exclusivity and how the industry is reacting.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zag Bio™, Inc., a biotechnology company pioneering thymus-targeted medicines, today announced the appointment of Jan Hillson, M.D., a physician-scientist and ...

Zag Bio™, Inc., a biotechnology company pioneering thymus-targeted medicines, today announced the appointment of Jan Hillson, M.D., a physician-scientist and rheumatologist with over 20 years of ...

Sanofi SNY announced that the European Commission has approved Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes (T1D) in patients aged eight years and older with stage 2 disease.

Artificial intelligence is moving quickly into drug discovery as pharmaceutical and biotech companies look for ways to cut years off R&D timelines and increase the chances of success amid rising costs ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Boston biotech executive whose ...

Sanofi SNY announced that the FDA has accepted a regulatory filing seeking to expand the use of its type 1 diabetes (T1D) drug, Tzield (teplizumab), in individuals aged one year and older. The agency ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Generation Bio, which once ...

We now know what Bianca Censori’s BIO POP (THE ORIGIN) is, and furniture does play a key part after all. Thursday (Dec. 11), Censori launched the previously teased project in Seoul, revealing—as had ...

Curi Bio’s ribbon cutting in April 2025 for its new headquarters on Seattle’s waterfront. Elliot Fisher, co-founder and chief business officer, cuts the ribbon with a sword while CEO Nicholas Geisse ...